...
search icon
jazz-img

Jazz Pharmaceuticals PLC, Common Stock

JAZZ

NSQ

$110.8

+$1.82

(1.67%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.09B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
12.5988
Volume info-icon
This is the total number of shares traded during the most recent trading day.
896.34K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.42
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$95.49 L
$148.06 H
$110.8

About Jazz Pharmaceuticals PLC, Common Stock

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameJAZZSectorS&P500
1-Week Return10.42%3.64%6.36%
1-Month Return-18.08%-5.42%-5.32%
3-Month Return-10.93%-6.89%-8.86%
6-Month Return1.14%-7.54%-5.61%
1-Year Return3.14%-1.81%8.61%
3-Year Return-33.31%2.1%27.58%
5-Year Return0.64%35.25%90.38%
10-Year Return-39.45%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue2.36B3.09B3.66B3.83B4.07B[{"date":"2020-12-31","value":58.09,"profit":true},{"date":"2021-12-31","value":76.05,"profit":true},{"date":"2022-12-31","value":89.93,"profit":true},{"date":"2023-12-31","value":94.23,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue148.92M440.76M540.52M435.58M445.71M[{"date":"2020-12-31","value":27.55,"profit":true},{"date":"2021-12-31","value":81.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.59,"profit":true},{"date":"2024-12-31","value":82.46,"profit":true}]
Gross Profit2.21B2.65B3.12B3.40B4.07B[{"date":"2020-12-31","value":54.43,"profit":true},{"date":"2021-12-31","value":65.21,"profit":true},{"date":"2022-12-31","value":76.65,"profit":true},{"date":"2023-12-31","value":83.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin93.70%85.76%85.23%88.64%100.00%[{"date":"2020-12-31","value":93.7,"profit":true},{"date":"2021-12-31","value":85.76,"profit":true},{"date":"2022-12-31","value":85.23,"profit":true},{"date":"2023-12-31","value":88.64,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses1.45B2.48B2.61B2.82B3.35B[{"date":"2020-12-31","value":43.23,"profit":true},{"date":"2021-12-31","value":74.07,"profit":true},{"date":"2022-12-31","value":77.75,"profit":true},{"date":"2023-12-31","value":84.12,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income765.46M170.28M512.27M578.58M716.63M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":22.25,"profit":true},{"date":"2022-12-31","value":66.92,"profit":true},{"date":"2023-12-31","value":75.59,"profit":true},{"date":"2024-12-31","value":93.62,"profit":true}]
Total Non-Operating Income/Expense(202.69M)(561.88M)(595.50M)(573.89M)(484.38M)[{"date":"2020-12-31","value":-20268500000,"profit":false},{"date":"2021-12-31","value":-56188200000,"profit":false},{"date":"2022-12-31","value":-59549800000,"profit":false},{"date":"2023-12-31","value":-57389000000,"profit":false},{"date":"2024-12-31","value":-48437600000,"profit":false}]
Pre-Tax Income275.10M(112.84M)(372.78M)297.93M470.35M[{"date":"2020-12-31","value":58.49,"profit":true},{"date":"2021-12-31","value":-23.99,"profit":false},{"date":"2022-12-31","value":-79.26,"profit":false},{"date":"2023-12-31","value":63.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes33.52M216.12M(158.65M)(119.91M)(89.77M)[{"date":"2020-12-31","value":15.51,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-73.41,"profit":false},{"date":"2023-12-31","value":-55.49,"profit":false},{"date":"2024-12-31","value":-41.54,"profit":false}]
Income After Taxes241.58M(328.95M)(214.14M)417.84M560.12M[{"date":"2020-12-31","value":43.13,"profit":true},{"date":"2021-12-31","value":-58.73,"profit":false},{"date":"2022-12-31","value":-38.23,"profit":false},{"date":"2023-12-31","value":74.6,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations241.58M(329.67M)(214.14M)79.95M560.12M[{"date":"2020-12-31","value":43.13,"profit":true},{"date":"2021-12-31","value":-58.86,"profit":false},{"date":"2022-12-31","value":-38.23,"profit":false},{"date":"2023-12-31","value":14.27,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income238.62M(328.95M)(214.14M)414.83M560.12M[{"date":"2020-12-31","value":42.6,"profit":true},{"date":"2021-12-31","value":-58.73,"profit":false},{"date":"2022-12-31","value":-38.23,"profit":false},{"date":"2023-12-31","value":74.06,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)12.4716.2313.1318.3221.19[{"date":"2020-12-31","value":58.85,"profit":true},{"date":"2021-12-31","value":76.59,"profit":true},{"date":"2022-12-31","value":61.96,"profit":true},{"date":"2023-12-31","value":86.46,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

JAZZ
Cash Ratio 2.88
Current Ratio 4.46
Quick Ratio 3.99

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

JAZZ
ROA (LTM) 4.60%
ROE (LTM) 14.31%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

JAZZ
Debt Ratio Lower is generally better. Negative is bad. 0.66
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

JAZZ
Trailing PE 12.81
Forward PE 4.79
P/S (TTM) 1.65
P/B 1.64
Price/FCF 17
EV/R 2.43
EV/Ebitda 7.23
PEG 0.33

FAQs

What is Jazz Pharmaceuticals PLC share price today?

Jazz Pharmaceuticals PLC (JAZZ) share price today is $110.8

Can Indians buy Jazz Pharmaceuticals PLC shares?

Yes, Indians can buy shares of Jazz Pharmaceuticals PLC (JAZZ) on Vested. To buy Jazz Pharmaceuticals PLC from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in JAZZ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Jazz Pharmaceuticals PLC be purchased?

Yes, you can purchase fractional shares of Jazz Pharmaceuticals PLC (JAZZ) via the Vested app. You can start investing in Jazz Pharmaceuticals PLC (JAZZ) with a minimum investment of $1.

How to invest in Jazz Pharmaceuticals PLC shares from India?

You can invest in shares of Jazz Pharmaceuticals PLC (JAZZ) via Vested in three simple steps:

  • Click on Sign Up or Invest in JAZZ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Jazz Pharmaceuticals PLC shares
What is Jazz Pharmaceuticals PLC 52-week high and low stock price?

The 52-week high price of Jazz Pharmaceuticals PLC (JAZZ) is $148.06. The 52-week low price of Jazz Pharmaceuticals PLC (JAZZ) is $95.49.

What is Jazz Pharmaceuticals PLC price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Jazz Pharmaceuticals PLC (JAZZ) is 12.5988

What is Jazz Pharmaceuticals PLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Jazz Pharmaceuticals PLC (JAZZ) is 1.64

What is the Market Cap of Jazz Pharmaceuticals PLC?

The market capitalization of Jazz Pharmaceuticals PLC (JAZZ) is $6.09B

What is Jazz Pharmaceuticals PLC’s stock symbol?

The stock symbol (or ticker) of Jazz Pharmaceuticals PLC is JAZZ

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top